Apricus Biosciences (NASDAQ:APRI) saw unusually-high trading volume on Thursday . Approximately 5,671,777 shares changed hands during trading, an increase of 303% from the previous session’s volume of 1,406,143 shares.The stock last traded at $0.46 and had previously closed at $0.38.
APRI has been the subject of a number of analyst reports. Zacks Investment Research upgraded Apricus Biosciences from a “strong sell” rating to a “hold” rating in a research report on Wednesday, January 3rd. HC Wainwright set a $5.00 price target on Apricus Biosciences and gave the stock a “buy” rating in a research report on Tuesday, January 16th. Finally, ValuEngine upgraded Apricus Biosciences from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd.
The stock has a market capitalization of $9.17, a P/E ratio of -0.46 and a beta of 1.34.
A hedge fund recently bought a new stake in Apricus Biosciences stock. Healthcare Value Capital LLC purchased a new position in Apricus Biosciences (NASDAQ:APRI) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 100,000 shares of the company’s stock, valued at approximately $184,000. Apricus Biosciences makes up 0.6% of Healthcare Value Capital LLC’s holdings, making the stock its 8th biggest position. Healthcare Value Capital LLC owned approximately 0.66% of Apricus Biosciences as of its most recent SEC filing. 18.61% of the stock is currently owned by hedge funds and other institutional investors.
About Apricus Biosciences
Apricus Biosciences, Inc, a biopharmaceutical company, focuses on the development of product candidates in the areas of urology and rheumatology. The company develops Vitaros, a topically-applied cream formulation of alprostadil used for the treatment of erectile dysfunction; and RayVa, which is in Phase IIa clinical trial to treat Raynaud's phenomenon associated with scleroderma.
Receive News & Ratings for Apricus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.